Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Pulmonary Drugs Market Size Forecast: How Large Could The Market Become By 2030?
The pulmonary drugs market has experienced robust expansion over recent years, with projections indicating growth from $56.98 billion in 2025 to $60.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.4%. This historical period’s progress was driven by factors such as a higher prevalence of asthma, an increasing incidence of chronic obstructive pulmonary disease (COPD), urban air pollution intensification, broader adoption of inhalation drug delivery systems, and enhanced diagnostic methods for respiratory conditions.
The pulmonary drugs market is projected to experience robust expansion over the coming years, with its value anticipated to reach $74.14 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.4%. This forecasted growth is driven by factors such as an increasing elderly population, the development of biologic pulmonary medications, the integration of precision respiratory medicine, a higher prevalence of smoking-related conditions, and enhanced availability of inhaled therapies. Key trends shaping the market during this period include a growing emphasis on targeted respiratory therapies, the emergence of combination inhalation products, a stronger focus on long-term disease management, the expansion of biologic-based pulmonary treatments, and a transition toward personalized respiratory care.
Download A Free Sample Report For Comprehensive Market Insights:
Pulmonary Drugs Market Growth Factors Supporting Long-Term Expansion
The pulmonary drugs market is experiencing growth driven by the rising prevalence of respiratory diseases, which impair normal breathing and oxygen exchange by affecting the lungs and airways. An increase in respiratory disorders is linked to factors such as higher smoking rates, which cause lung damage and contribute to chronic conditions, while pulmonary drugs are essential for managing these issues by enhancing lung function, reducing inflammation, and alleviating airway obstructions to facilitate better breathing. Data from the Centers for Disease Control and Prevention, a US-based government agency, indicated in May 2025 that in 2023, age-adjusted COPD prevalence among adults 18 and older stood at 3.8%, with rates higher in women at 4.1% compared to men at 3.4%, and this prevalence increased sharply with age from 0.4% in those aged 18–24 to 10.5% in individuals 75 and older. Consequently, the escalating incidence of respiratory diseases is fueling expansion in the pulmonary drugs market.
Pulmonary Drugs Market Segmentation And Category Breakdown
The pulmonary drugs market covered in this report is segmented –
1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes
Pulmonary Drugs Market Industry Trends Shaping Future Revenue Growth
Key players in the pulmonary drugs market are concentrating on therapeutic breakthroughs, including the use of inhaled dual PDE3 and PDE4 inhibition, which delivers both bronchodilator and non-steroidal anti-inflammatory effects in a single compound for long-term COPD management. This dual inhibition allows airway dilation and decreases lung inflammation simultaneously, tackling ongoing COPD symptoms more efficiently compared to conventional treatments and streamlining dosing without needing intricate inhalation methods. For example, in June 2024, Verona Pharma plc, a biopharmaceutical firm based in the UK, gained U.S. FDA approval for Ohtuvayre (ensifentrine), the first inhaled medication in over two decades to feature this dual-action mechanism. Administered with a standard jet nebulizer, Ohtuvayre offers bronchodilation and anti-inflammatory action in one dose, demonstrating clinical effectiveness as a standalone therapy or combined with other maintenance drugs in the Phase 3 ENHANCE trials, and is set to become accessible via U.S. specialty pharmacies by the third quarter of 2024.
Pulmonary Drugs Market Competitive Analysis Of Major Industry Participants
Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.
Access The Complete Pulmonary Drugs Market Report:
Pulmonary Drugs Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model